Pub Date : 2026-01-05DOI: 10.1016/j.carrev.2025.12.023
Beni Rai Verma, Abhinav Sood, Kalyan Chitturi, Abdullah Al Qaraghuli, Dan Haberman, Cheng Zhang, Sevket T Ozturk, Vaishnavi Sawant, Yama Thakkar, Jason Galo, Waiel Abusnina, Itsik Ben-Dor, Brian C Case, Hayder Hashim, Ron Waksman
<p><strong>Background: </strong>The Danish-German (DanGer) Shock trial demonstrated that the use of a microaxial flow pump (Impella) reduced mortality compared to medical management in patients with acute ST elevation myocardial infarction complicated with cardiogenic shock (STEMI-CS). However, patients in the control arm of the DanGer Shock trial were not treated with an intra-aortic balloon pump (IABP), and data directly comparing Impella to IABP in this population is limited.</p><p><strong>Methods: </strong>We identified STEMI-CS patients treated with percutaneous coronary intervention (PCI) and IABP at our institution between January 1, 2013, and February 20, 2025. These patients were screened according to the selection criteria of the DanGer Shock trial and were compared to the Impella MCS device 2.5 or CP and standard-of-medical-care (SoMC) arms of the DanGer Shock trial.</p><p><strong>Results: </strong>Our cohort included 102 STEMI-CS patients treated with IABP. Compared to Impella CP patients from the DanGer Shock trial, IABP patients had significantly higher rates of hypertension, diabetes mellitus, heart failure, and SCAI stage E cardiogenic shock, but significantly lower rates of mechanical ventilation, vasopressor, and inotrope use. At 180 days, IABP patients had similar all-cause mortality compared to Impella CP patients (35.9 % vs. 45.8 %, p = 0.06), and lower rates of major bleeding (6 % vs. 39 %, p < 0.001) and renal replacement therapy (8 % vs. 75 %, p < 0.001). Additionally, IABP patients had lower mortality compared to SoMC patients (35.9 % vs. 58.5 %, p = 0.0004).</p><p><strong>Conclusion: </strong>These findings support the hypothesis that STEMI-CS patients treated with IABP have comparable 180-day mortality to those treated with Impella CP and lower mortality than those receiving standard medical care. STEMI-CS cohort is heterogenous and IABP use may be beneficial in certain patients. Well-designed randomized trials comparing Impella CP and IABP in this patient population are warranted to inform clinical decision-making.</p><p><strong>Condensed abstract: </strong>Acute ST elevation myocardial infarction complicated with cardiogenic shock (STEMI-CS) portends a high mortality risk. New American guidelines now recommend a peripherally inserted left ventricular assist device, such as Impella, as a Class II indication for the management of STEMI-CS patients. Further, guidelines now give intra-aortic balloon pump (IABP) as a class III indication for these patients. However, there is a need of direct head-to-head comparison of these two mechanical support modalities in this specific subset of patients. In this analysis, we identified STEMI-CS patients treated with IABP at our institution and compared them to the Impella CP cohort from the DanGer Shock trial. We found that both modalities had similar mortality rates, and IABP has lower mortality rates when compared to standard medical cohort from the trial. However, despite applying
背景：丹麦-德国（DanGer）休克试验表明，与药物治疗相比，使用微轴流泵（Impella）可降低急性ST段抬高型心肌梗死合并心源性休克（STEMI-CS）患者的死亡率。然而，在危险休克试验的对照组中，患者没有接受主动脉内球囊泵（IABP）治疗，在该人群中直接比较Impella和IABP的数据有限。方法：选取2013年1月1日至2025年2月20日在我院接受经皮冠状动脉介入治疗（PCI）和IABP治疗的STEMI-CS患者。根据危险休克试验的选择标准筛选这些患者，并将其与危险休克试验的Impella MCS装置2.5或CP和标准医疗护理（SoMC）组进行比较。结果：我们的队列包括102例接受IABP治疗的STEMI-CS患者。与来自DanGer Shock试验的Impella CP患者相比，IABP患者的高血压、糖尿病、心力衰竭和SCAI E期心源性休克的发生率明显较高，但机械通气、血管加压药和肌力药物的使用率明显较低。180天时，IABP患者的全因死亡率与Impella CP患者相似（35.9% vs. 45.8%, p = 0.06），大出血率更低（6% vs. 39%, p）。结论：这些发现支持STEMI-CS患者接受IABP治疗的180天死亡率与Impella CP治疗的患者相当，死亡率低于接受标准医疗护理的患者。STEMI-CS队列是异质性的，使用IABP可能对某些患者有益。设计良好的随机试验比较Impella CP和IABP在该患者群体中有必要为临床决策提供信息。摘要：急性ST段抬高型心肌梗死合并心源性休克（STEMI-CS）具有较高的死亡风险。新的美国指南现在推荐外周插入的左心室辅助装置，如Impella，作为STEMI-CS患者治疗的II级指证。此外，指南现在将主动脉内球囊泵（IABP）作为这些患者的III级指征。然而，在这一特定的患者群体中，需要对这两种机械支持方式进行直接的比较。在本分析中，我们确定了我院接受IABP治疗的STEMI-CS患者，并将其与来自DanGer Shock试验的Impella CP队列进行了比较。我们发现两种方式的死亡率相似，与试验中的标准医学队列相比，IABP的死亡率更低。然而，尽管应用了危险休克选择标准，组间差异仍然存在。与Impella CP相比，IABP的并发症发生率更低。这些发现支持IABP在某些STEMI-CS患者的治疗中使用，其临床应用不应被低估。
{"title":"Comparison of clinical outcomes of acute myocardial infarction patients complicated with cardiogenic shock treated with intra-aortic balloon pump versus microaxial flow pump.","authors":"Beni Rai Verma, Abhinav Sood, Kalyan Chitturi, Abdullah Al Qaraghuli, Dan Haberman, Cheng Zhang, Sevket T Ozturk, Vaishnavi Sawant, Yama Thakkar, Jason Galo, Waiel Abusnina, Itsik Ben-Dor, Brian C Case, Hayder Hashim, Ron Waksman","doi":"10.1016/j.carrev.2025.12.023","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.12.023","url":null,"abstract":"<p><strong>Background: </strong>The Danish-German (DanGer) Shock trial demonstrated that the use of a microaxial flow pump (Impella) reduced mortality compared to medical management in patients with acute ST elevation myocardial infarction complicated with cardiogenic shock (STEMI-CS). However, patients in the control arm of the DanGer Shock trial were not treated with an intra-aortic balloon pump (IABP), and data directly comparing Impella to IABP in this population is limited.</p><p><strong>Methods: </strong>We identified STEMI-CS patients treated with percutaneous coronary intervention (PCI) and IABP at our institution between January 1, 2013, and February 20, 2025. These patients were screened according to the selection criteria of the DanGer Shock trial and were compared to the Impella MCS device 2.5 or CP and standard-of-medical-care (SoMC) arms of the DanGer Shock trial.</p><p><strong>Results: </strong>Our cohort included 102 STEMI-CS patients treated with IABP. Compared to Impella CP patients from the DanGer Shock trial, IABP patients had significantly higher rates of hypertension, diabetes mellitus, heart failure, and SCAI stage E cardiogenic shock, but significantly lower rates of mechanical ventilation, vasopressor, and inotrope use. At 180 days, IABP patients had similar all-cause mortality compared to Impella CP patients (35.9 % vs. 45.8 %, p = 0.06), and lower rates of major bleeding (6 % vs. 39 %, p < 0.001) and renal replacement therapy (8 % vs. 75 %, p < 0.001). Additionally, IABP patients had lower mortality compared to SoMC patients (35.9 % vs. 58.5 %, p = 0.0004).</p><p><strong>Conclusion: </strong>These findings support the hypothesis that STEMI-CS patients treated with IABP have comparable 180-day mortality to those treated with Impella CP and lower mortality than those receiving standard medical care. STEMI-CS cohort is heterogenous and IABP use may be beneficial in certain patients. Well-designed randomized trials comparing Impella CP and IABP in this patient population are warranted to inform clinical decision-making.</p><p><strong>Condensed abstract: </strong>Acute ST elevation myocardial infarction complicated with cardiogenic shock (STEMI-CS) portends a high mortality risk. New American guidelines now recommend a peripherally inserted left ventricular assist device, such as Impella, as a Class II indication for the management of STEMI-CS patients. Further, guidelines now give intra-aortic balloon pump (IABP) as a class III indication for these patients. However, there is a need of direct head-to-head comparison of these two mechanical support modalities in this specific subset of patients. In this analysis, we identified STEMI-CS patients treated with IABP at our institution and compared them to the Impella CP cohort from the DanGer Shock trial. We found that both modalities had similar mortality rates, and IABP has lower mortality rates when compared to standard medical cohort from the trial. However, despite applying","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1016/j.carrev.2025.12.024
Ehab Cherif, Husam Abdulaziz Noor
Background: Hybrid drug-eluting stent/drug-coated balloon percutaneous coronary intervention (DES-DCB PCI) aims to minimize stent burden while maintaining patency in chronic total occlusion lesions.
Methods: We prospectively studied 19 consecutive CTO patients treated with a hybrid DES-DCB strategy; primary endpoint was late lumen loss (LLL) at 3-4 months, with secondary clinical outcomes at six months.
Results: Technical success was 89.5 %; mean LLL was 0.10 ± 0.83 mm; late lumen gain occurred in ~53 % of patients completing angiographic follow-up; binary restenosis was 10.5 %. Residual stenosis strongly predicted LLL, while optimal DCB sizing and inflation ≥180 s were protective; residual stenosis remained the independent predictor in multivariable regression. IVUS guidance was associated with 0 % restenosis.
Conclusions: Hybrid DES-DCB PCI for CTOs was feasible with low LLL. Outcomes hinged on lesion preparation, sizing, and inflation duration. The six-component GLOW score provides intra-procedural risk stratification and warrants multicenter validation.
{"title":"Hybrid (DES + DCB) strategy for chronic total occlusions: Development of the GLOW risk stratification score.","authors":"Ehab Cherif, Husam Abdulaziz Noor","doi":"10.1016/j.carrev.2025.12.024","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.12.024","url":null,"abstract":"<p><strong>Background: </strong>Hybrid drug-eluting stent/drug-coated balloon percutaneous coronary intervention (DES-DCB PCI) aims to minimize stent burden while maintaining patency in chronic total occlusion lesions.</p><p><strong>Methods: </strong>We prospectively studied 19 consecutive CTO patients treated with a hybrid DES-DCB strategy; primary endpoint was late lumen loss (LLL) at 3-4 months, with secondary clinical outcomes at six months.</p><p><strong>Results: </strong>Technical success was 89.5 %; mean LLL was 0.10 ± 0.83 mm; late lumen gain occurred in ~53 % of patients completing angiographic follow-up; binary restenosis was 10.5 %. Residual stenosis strongly predicted LLL, while optimal DCB sizing and inflation ≥180 s were protective; residual stenosis remained the independent predictor in multivariable regression. IVUS guidance was associated with 0 % restenosis.</p><p><strong>Conclusions: </strong>Hybrid DES-DCB PCI for CTOs was feasible with low LLL. Outcomes hinged on lesion preparation, sizing, and inflation duration. The six-component GLOW score provides intra-procedural risk stratification and warrants multicenter validation.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.carrev.2025.12.025
Mehmet Cilingiroglu, Ibrahim Inanc
{"title":"Do we still need routine pre-discharge echocardiography after LAAC?","authors":"Mehmet Cilingiroglu, Ibrahim Inanc","doi":"10.1016/j.carrev.2025.12.025","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.12.025","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.carrev.2025.12.026
Adham Ramadan, Michael Megaly
{"title":"Editorial: Intravascular brachytherapy for in-stent restenosis: The role of vessel size.","authors":"Adham Ramadan, Michael Megaly","doi":"10.1016/j.carrev.2025.12.026","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.12.026","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-02DOI: 10.1016/j.carrev.2025.12.027
Grant W Reed, Evan H Whitehead
{"title":"Editorial: ICE versus TEE: Redefining image guidance for left atrial appendage occlusion.","authors":"Grant W Reed, Evan H Whitehead","doi":"10.1016/j.carrev.2025.12.027","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.12.027","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2026-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.carrev.2025.04.013
Lin Wang , Luca Paolucci , Angela McInerney , Fernando Alfonso , David del Val , Enrico Cerrato , Juan Garcia de Lara , Eduardo Pinar , Armando Perez de Prado , Salvatore Brugaletta , Andrea Ruberti , Manel Sabaté , Héctor Cubero Gallego , Beatriz Vaquerizo , Alfonso Jurado-Román , Ferdinando Varbella , Marcelo Jimenez , Artemio Garcia Escobar , José María de la Torre , Ignacio Amat Santos , Nieves Gonzalo
Background
The effectiveness of intravascular lithotripsy (IVL) in terms of anatomical and physiological results in different subtypes of calcifications is unknown.
Methods
Lesions treated with IVL-percutaneous coronary intervention (PCI) were stratified according to hemodynamic pattern (focal/diffuse) and calcification phenotypes (concentric/eccentric). All lesions were analyzed with optical coherence tomography (OCT), OCT-based fractional flow reserve (OFR) and quantitative flow ratio (QFR). The outcomes were post-PCI OFR/QFR values, minimal stent area (MSA) and angio-derived index of microvascular resistance (Angio-IMR).
Results
88 lesions were included. All parameters significantly increased during PCI. Diffuse lesions showed lower post-PCI values of OFR (focal = 0.92 (0.89–0.95) vs diffuse = 0.88 (0.85–0.91), P < 0.01), QFR (focal = 0.94 (0.89–0.98) vs diffuse = 0.87 (0.85–0.90); P < 0.01) and MSA (focal = 6.40 (5.80–7.10) mm2 vs diffuse = 5.40 (4.80–6.00) mm2, P = 0.02). Angio-IMR changes were comparable between the two groups. No differences were evident between concentric and eccentric lesions for any outcomes assessed.
Conclusions
Diffuse lesions were associated with suboptimal anatomical and physiological results following IVL-PCI, while no differences were evident between concentric and eccentric calcification phenotypes.
{"title":"Impact of lesion hemodynamic pattern and calcium morphology on the functional efficacy of coronary intravascular lithotripsy","authors":"Lin Wang , Luca Paolucci , Angela McInerney , Fernando Alfonso , David del Val , Enrico Cerrato , Juan Garcia de Lara , Eduardo Pinar , Armando Perez de Prado , Salvatore Brugaletta , Andrea Ruberti , Manel Sabaté , Héctor Cubero Gallego , Beatriz Vaquerizo , Alfonso Jurado-Román , Ferdinando Varbella , Marcelo Jimenez , Artemio Garcia Escobar , José María de la Torre , Ignacio Amat Santos , Nieves Gonzalo","doi":"10.1016/j.carrev.2025.04.013","DOIUrl":"10.1016/j.carrev.2025.04.013","url":null,"abstract":"<div><h3>Background</h3><div>The effectiveness of intravascular lithotripsy (IVL) in terms of anatomical and physiological results in different subtypes of calcifications is unknown.</div></div><div><h3>Methods</h3><div>Lesions treated with IVL-percutaneous coronary intervention (PCI) were stratified according to hemodynamic<span> pattern (focal/diffuse) and calcification phenotypes (concentric/eccentric). All lesions were analyzed with optical coherence tomography<span> (OCT), OCT-based fractional flow reserve (OFR) and quantitative flow ratio (QFR). The outcomes were post-PCI OFR/QFR values, minimal stent area (MSA) and angio-derived index of microvascular resistance (Angio-IMR).</span></span></div></div><div><h3>Results</h3><div>88 lesions were included. All parameters significantly increased during PCI. Diffuse lesions showed lower post-PCI values of OFR (focal = 0.92 (0.89–0.95) vs diffuse = 0.88 (0.85–0.91), <em>P</em> < 0.01), QFR (focal = 0.94 (0.89–0.98) vs diffuse = 0.87 (0.85–0.90); P < 0.01) and MSA (focal = 6.40 (5.80–7.10) mm<sup>2</sup> vs diffuse = 5.40 (4.80–6.00) mm<sup>2</sup>, <em>P</em> = 0.02). Angio-IMR changes were comparable between the two groups. No differences were evident between concentric and eccentric lesions for any outcomes assessed.</div></div><div><h3>Conclusions</h3><div>Diffuse lesions were associated with suboptimal anatomical and physiological results following IVL-PCI, while no differences were evident between concentric and eccentric calcification phenotypes.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 1-8"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.carrev.2025.04.008
Michał Piotrowski , Julia Izabela Karpierz , Jakub Batko , Marian Burysz , Krzysztof Bartuś
Background
Patent foramen ovale and atrial septal defect are among the most common congenital heart diseases. When they are symptomatic, either pharmacologic or percutaneous/surgical treatment should be considered. The aim of this study was to investigate the post-approval complication profiles of the Gore Cardioform and Gore Helex devices based on the Manufacturer and User Facility Device Experience database.
Methods
A search of the Manufacturer and User Facility Device Experience Database was performed to identify reports of complications following the closure of atrial septal defects with Gore devices. 401 reports met inclusion criteria, including 204 patients with Gore Cardioform Septal Occluder, 146 patients with Gore Cardioform ASD Occluder, and 51 patients with Gore Helex Septal Occluder.
Results
The number of adverse events related to device problems contributed to 51.4 % of reported complications (n = 206), which mostly consisted of embolism of the device (n = 140). There were 3 reported cases of death, with 2 linked to device embolization. Most reports concerned devices sized 25 and 30 mm although only 313 reports (78.1 %) had information about size available. 54 cases of pericardial effusion and 14 cases of perforation were reported. Multiple postoperative arrhythmias were reported (n = 80), with the majority of them being atrial fibrillation (n = 39) or heart block (n = 18).
Conclusions
No cardiac erosions linked to Gore devices were found throughout our analysis, supporting earlier literature findings. The investigated devices and their sizes varied in terms of complication profiles.
{"title":"Atrial septal defect and patent foramen ovale closure- complication profile of approved Gore Occluders","authors":"Michał Piotrowski , Julia Izabela Karpierz , Jakub Batko , Marian Burysz , Krzysztof Bartuś","doi":"10.1016/j.carrev.2025.04.008","DOIUrl":"10.1016/j.carrev.2025.04.008","url":null,"abstract":"<div><h3>Background</h3><div>Patent foramen ovale<span> and atrial septal defect<span> are among the most common congenital heart diseases. When they are symptomatic, either pharmacologic or percutaneous/surgical treatment should be considered. The aim of this study was to investigate the post-approval complication profiles of the Gore Cardioform and Gore Helex devices based on the Manufacturer and User Facility Device Experience database.</span></span></div></div><div><h3>Methods</h3><div>A search of the Manufacturer and User Facility Device Experience Database was performed to identify reports of complications following the closure of atrial septal defects with Gore devices. 401 reports met inclusion criteria, including 204 patients with Gore Cardioform Septal Occluder, 146 patients with Gore Cardioform ASD Occluder, and 51 patients with Gore Helex Septal Occluder.</div></div><div><h3>Results</h3><div>The number of adverse events related to device problems contributed to 51.4 % of reported complications (<em>n</em> = 206), which mostly consisted of embolism of the device (<em>n</em><span> = 140). There were 3 reported cases of death, with 2 linked to device embolization<span>. Most reports concerned devices sized 25 and 30 mm although only 313 reports (78.1 %) had information about size available. 54 cases of pericardial effusion and 14 cases of perforation were reported. Multiple postoperative arrhythmias were reported (</span></span><em>n</em> = 80), with the majority of them being atrial fibrillation (<em>n</em> = 39) or heart block (<em>n</em> = 18).</div></div><div><h3>Conclusions</h3><div>No cardiac erosions linked to Gore devices were found throughout our analysis, supporting earlier literature findings. The investigated devices and their sizes varied in terms of complication profiles.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 84-90"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.carrev.2025.05.025
Robert S. Dieter , Robert S. Dieter II , Elizabeth G. Dieter
{"title":"Expanding the differential for a bounding popliteal artery pulsation on physical exam","authors":"Robert S. Dieter , Robert S. Dieter II , Elizabeth G. Dieter","doi":"10.1016/j.carrev.2025.05.025","DOIUrl":"10.1016/j.carrev.2025.05.025","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 127-128"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.carrev.2025.08.002
Flavio L. Ribichini
{"title":"Editorial: Renal denervation for kidney-related pain syndromes: a clue in search of proofs","authors":"Flavio L. Ribichini","doi":"10.1016/j.carrev.2025.08.002","DOIUrl":"10.1016/j.carrev.2025.08.002","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"82 ","pages":"Pages 21-22"},"PeriodicalIF":1.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144795854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：